Myocardial Infarction Therapeutics Pipeline Analysis, 2017

The myocardial infarction therapeutics pipeline is expected to increase in future due to rise in prevalence of myocardial infarction. Myocardial infarction is also commonly known as heart attack which is symptomatized by decrease in blood supply to the heart muscle due to coronary artery disease. According to American Heart Association, the mortality rate due to cardiovascular disease is higher than other disease. According to British Heart Foundation, in 2015, around 150,155 deaths, occurred due to cardiovascular disease in the U.K. Some of the drivers for the growth of the myocardial infarction therapeutics pipeline include increasing incidence of coronary artery disease, change in lifestyle, lack of exercise, increase in incidence of blood pressure and obesity. According to World Health Organization (WHO), there has been an increase in incidence of heart disease in smokers as compared to non-smokers.

Explore Report at: www.psmarketresearch.com/market-analysis/myocardial-infarction-therapeutics-pipeline-analysis

The myocardial infarction is a state of blockage of flow of oxygen-rich blood to a section of heart muscle, leading to the death of muscle. Myocardial infarction most often occurs in case of coronary artery disease in which a waxy substance, known as plaque gets build up inside the coronary artery, decreasing the oxygen-rich blood supply to the heart. This condition is also known as atherosclerosis due to which area of plaque break open inside a coronary artery, leading to the formation of clot. This clot gets bigger with time and leads to the blockage of coronary artery. The heart failure is a condition in which heart cannot pump enough blood to meet the body need. In various cases, a discomfort occurs in the center or left side of the chest which can last for few minutes which goes away and comes back. The upper body discomfort and shortness of breath also occurs in case of cardiac disorders.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/myocardial-infarction-therapeutics-pipeline-analysis/toc-sample

Many institutes, associations and companies are collaborating for the development of therapeutic treatments for myocardial infarction. Eli Lilly and Company collaborated with Centocor, Inc. to conduct clinical trials for efficacy and safety of reteplease and abciximab combination therapy, with abciximab alone administered early or just prior to primary percutaneous coronary intervention.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the key players having a pipeline of myocardial infarction therapeutics include Pfizer Inc., Novartis N.V., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, AstraZeneca, Apotex Inc., Par Pharmaceutical Companies, Inc., Sandoz, Mylan N.V.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY - 10016

This release was published on openPR.